John J.P. Kastelein

机构：Korea Pharma (South Korea), QRx Pharma (United States), University of Amsterdam · ORCID：0000-0003-2018-4532

发表论文 1125 篇 · 总被引 138665 次 · h-index 167

代表论文

• Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk (2025 · New England Journal of Medicine · 被引 98)
• Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial (2025 · The Lancet · 被引 54)
• Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients (2025 · Journal of the American College of Cardiology · 被引 34)
• Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease (2025 · The Journal of Prevention of Alzheimer s Disease · 被引 11)
• Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics (2025 · American Heart Journal · 被引 10)
• Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial (2026 · Nature Medicine · 被引 8)